Better Living Through Chemistry: Biopharma Investors Weigh In

In our third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare disease are top investment targets.

More from Strategy

More from Business